Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1

Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1 Oncol Ther (2019) 7:121–130 https://doi.org/10.1007/s40487-019-0095-9 ORIGINAL RESEARCH Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1 . . . . Etienne Paubelle Adriana Plesa Sandrine Hayette Mohamed Elhamri . . . Florence Zylbersztejn Olivier Hermine Gilles Salles Xavier Thomas Received: January 9, 2019 / Published online: May 22, 2019 The Author(s) 2019 addition of ATRA might be of benefit in the ABSTRACT treatment of patients with EVI1-positive AML. Introduction: EVI1 (MECOM)-positive acute Keywords: Acute myeloid leukemia; All-trans- myeloid leukemia (AML) cells have shown retinoic acid; EVI1; Leukemia stem cells; in vitro sensitivity to all-trans-retinoic acid MECOM (ATRA) by inducing differentiation, cell death, and decreased leukemic engraftment. Methods: In this pilot study, we investigated INTRODUCTION the response to ATRA in 13 high-risk AML patients with overexpression of EVI1. Acute myeloid leukemia (AML) is the predomi- Results: Seven of the 13 patients (53.8%) nant acute leukemia among adults, character- achieved complete remission (CR), and ized by an accumulation of malignant response can be combined with a decreased of immature myeloid precursors. It represents a the leukemia stem cell pool. heterogeneous group of diseases with different Conclusion: These primary results tend to responses to treatment, which can be http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1

Loading next page...
 
/lp/springer-journals/efficacy-of-all-trans-retinoic-acid-in-high-risk-acute-myeloid-z34YQpEz3n
Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-0095-9
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2019) 7:121–130 https://doi.org/10.1007/s40487-019-0095-9 ORIGINAL RESEARCH Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1 . . . . Etienne Paubelle Adriana Plesa Sandrine Hayette Mohamed Elhamri . . . Florence Zylbersztejn Olivier Hermine Gilles Salles Xavier Thomas Received: January 9, 2019 / Published online: May 22, 2019 The Author(s) 2019 addition of ATRA might be of benefit in the ABSTRACT treatment of patients with EVI1-positive AML. Introduction: EVI1 (MECOM)-positive acute Keywords: Acute myeloid leukemia; All-trans- myeloid leukemia (AML) cells have shown retinoic acid; EVI1; Leukemia stem cells; in vitro sensitivity to all-trans-retinoic acid MECOM (ATRA) by inducing differentiation, cell death, and decreased leukemic engraftment. Methods: In this pilot study, we investigated INTRODUCTION the response to ATRA in 13 high-risk AML patients with overexpression of EVI1. Acute myeloid leukemia (AML) is the predomi- Results: Seven of the 13 patients (53.8%) nant acute leukemia among adults, character- achieved complete remission (CR), and ized by an accumulation of malignant response can be combined with a decreased of immature myeloid precursors. It represents a the leukemia stem cell pool. heterogeneous group of diseases with different Conclusion: These primary results tend to responses to treatment, which can be

Journal

Oncology and TherapySpringer Journals

Published: May 22, 2019

References